MX2022013861A - Nuevos inhibidores macrociclicos de la quinasa de lrrk2. - Google Patents
Nuevos inhibidores macrociclicos de la quinasa de lrrk2.Info
- Publication number
- MX2022013861A MX2022013861A MX2022013861A MX2022013861A MX2022013861A MX 2022013861 A MX2022013861 A MX 2022013861A MX 2022013861 A MX2022013861 A MX 2022013861A MX 2022013861 A MX2022013861 A MX 2022013861A MX 2022013861 A MX2022013861 A MX 2022013861A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- lrrk2 kinase
- new macrocyclic
- macrocyclic lrrk2
- new
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Compuestos de la fórmula (I): (ver Fórmula) en donde R, X1, X2, X3, Z1, Z2, Z3, A y Ra son como se han definido en la descripción.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20315236 | 2020-05-06 | ||
EP21305112 | 2021-01-28 | ||
PCT/EP2021/061827 WO2021224320A1 (en) | 2020-05-06 | 2021-05-05 | New macrocyclic lrrk2 kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022013861A true MX2022013861A (es) | 2023-02-22 |
Family
ID=75746649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013861A MX2022013861A (es) | 2020-05-06 | 2021-05-05 | Nuevos inhibidores macrociclicos de la quinasa de lrrk2. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20230357269A1 (es) |
EP (1) | EP4146658A1 (es) |
JP (1) | JP2023523863A (es) |
KR (1) | KR20230006560A (es) |
CN (1) | CN115996932A (es) |
AU (1) | AU2021267691A1 (es) |
BR (1) | BR112022022511A2 (es) |
CA (1) | CA3182162A1 (es) |
CL (1) | CL2022003070A1 (es) |
CO (1) | CO2022015871A2 (es) |
CR (1) | CR20220561A (es) |
DO (1) | DOP2022000242A (es) |
IL (1) | IL297867A (es) |
MX (1) | MX2022013861A (es) |
PE (1) | PE20230612A1 (es) |
TW (1) | TW202208379A (es) |
UY (1) | UY39199A (es) |
WO (1) | WO2021224320A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3213388A1 (en) * | 2021-03-18 | 2022-09-22 | Les Laboratoires Servier | Macrocyclic lrrk2 kinase inhibitors |
CN117425660A (zh) * | 2022-05-18 | 2024-01-19 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其中间体、药物组合物和用途 |
WO2023240140A1 (en) * | 2022-06-08 | 2023-12-14 | Blossomhill Therapeutics, Inc. | Indazole macrocycles and their use |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE029728T2 (en) * | 2011-09-30 | 2017-03-28 | Ipsen Pharma Sas | Macrocyclic LRRK2 kinase inhibitors |
US9718818B2 (en) * | 2013-08-22 | 2017-08-01 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
PL3194405T4 (pl) | 2014-09-17 | 2019-07-31 | Oncodesign S.A. | Makrocykliczne inhibitory kinazy lrrk2 |
US10608658B2 (en) | 2016-07-04 | 2020-03-31 | Telefonaktiebolaget Lm Ericsson (Publ) | Pipelined analog-to-digital converter |
BR112019015314A2 (pt) | 2017-01-25 | 2020-05-19 | Glaxosmithkline Ip Dev Ltd | compostos para inibir a atividade da quinase lrrk2 |
EP3587422A4 (en) | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLO-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A PROTEIN KINASE-RELATED DISEASE |
BR112019018688A2 (pt) | 2017-03-10 | 2020-04-07 | Pfizer | derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2 |
WO2018217946A1 (en) | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
BR112020000772A2 (pt) | 2017-07-14 | 2020-07-21 | Glaxosmithkline Intellectual Property Development Limited | inibidores de cinase 2 de repetição rica em leucina |
US11161854B2 (en) | 2017-10-11 | 2021-11-02 | Merck Sharp & Dohme Corp. | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof |
US11370796B2 (en) | 2017-12-05 | 2022-06-28 | Oscotec Inc. | Substituted pyrazoles as LRRK2 inhibitors |
WO2019222173A1 (en) | 2018-05-15 | 2019-11-21 | E-Scape Bio, Inc. | Fused tetrazoles as lrrk2 inhibitors |
WO2019241540A1 (en) * | 2018-06-15 | 2019-12-19 | Samumed, Llc | Indazole containing macrocycles and therapeutic uses thereof |
TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
-
2021
- 2021-05-05 BR BR112022022511A patent/BR112022022511A2/pt unknown
- 2021-05-05 IL IL297867A patent/IL297867A/en unknown
- 2021-05-05 KR KR1020227042327A patent/KR20230006560A/ko active Search and Examination
- 2021-05-05 CA CA3182162A patent/CA3182162A1/en active Pending
- 2021-05-05 EP EP21722503.6A patent/EP4146658A1/en active Pending
- 2021-05-05 TW TW110116241A patent/TW202208379A/zh unknown
- 2021-05-05 CR CR20220561A patent/CR20220561A/es unknown
- 2021-05-05 MX MX2022013861A patent/MX2022013861A/es unknown
- 2021-05-05 CN CN202180044443.9A patent/CN115996932A/zh active Pending
- 2021-05-05 WO PCT/EP2021/061827 patent/WO2021224320A1/en active Application Filing
- 2021-05-05 AU AU2021267691A patent/AU2021267691A1/en active Pending
- 2021-05-05 PE PE2022002552A patent/PE20230612A1/es unknown
- 2021-05-05 JP JP2022567124A patent/JP2023523863A/ja active Pending
- 2021-05-05 US US17/923,002 patent/US20230357269A1/en active Pending
- 2021-05-06 UY UY0001039199A patent/UY39199A/es unknown
-
2022
- 2022-11-02 DO DO2022000242A patent/DOP2022000242A/es unknown
- 2022-11-03 CO CONC2022/0015871A patent/CO2022015871A2/es unknown
- 2022-11-04 CL CL2022003070A patent/CL2022003070A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021224320A1 (en) | 2021-11-11 |
IL297867A (en) | 2023-01-01 |
UY39199A (es) | 2021-11-30 |
CN115996932A (zh) | 2023-04-21 |
CA3182162A1 (en) | 2021-11-11 |
EP4146658A1 (en) | 2023-03-15 |
US20230357269A1 (en) | 2023-11-09 |
BR112022022511A2 (pt) | 2022-12-13 |
PE20230612A1 (es) | 2023-04-13 |
CO2022015871A2 (es) | 2022-12-30 |
DOP2022000242A (es) | 2023-07-31 |
JP2023523863A (ja) | 2023-06-07 |
CL2022003070A1 (es) | 2023-07-07 |
AU2021267691A1 (en) | 2022-12-08 |
CR20220561A (es) | 2023-02-17 |
KR20230006560A (ko) | 2023-01-10 |
TW202208379A (zh) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022013861A (es) | Nuevos inhibidores macrociclicos de la quinasa de lrrk2. | |
MX2009008506A (es) | Derivados del pirazol como inhibidores de 11-b-hsd1. | |
TN2019000263A1 (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
CA3139348A1 (en) | Heterocyclic compounds for inhibiting ras and uses thereof | |
WO2017109488A8 (en) | Cyanopyrrolidine derivatives as inhibitors for dubs | |
MX2009010595A (es) | Derivados de pirrolopirimidina. | |
PH12018502513A1 (en) | Sulfonamide compound or salt thereof | |
CA2983481A1 (en) | Janus kinase inhibitor | |
MY170823A (en) | Protein kinase inhibitors | |
MX2021008356A (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
GEP20207169B (en) | 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | |
MX2009007302A (es) | Derivados de purina. | |
RS53451B (en) | INHIBITORI P70 S6 KINAZE | |
MY148107A (en) | Kinase inhibitor | |
TN2018000087A1 (en) | New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors | |
TNSN08191A1 (en) | Kinase inhibitors | |
MX2022002976A (es) | Inhibidores selectivos de jak1. | |
MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
MX2009005071A (es) | Compuestos de pirazol y triazol sustituidos como inhibidores de ksp. | |
WO2020259724A3 (zh) | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 | |
CR20200151A (es) | Compuestos bicíclicos y métodos de utilización de los mismos | |
PH12021551251A1 (en) | Heterocyclic compound | |
NZ592392A (en) | PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | |
AP2002002466A0 (en) | 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS. | |
UY39680A (es) | Nuevos inhibidores macrocíclicos de la quinasa de lrrk2 |